Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers

E. J. Sims, M. C. Patterson, S. K. Das, H. B. Buck, B. J. Lipworth (St Albans, United Kingdom)

Source: Annual Congress 2002 - Lung disposition clinical outcomes: effect of delivery device
Session: Lung disposition clinical outcomes: effect of delivery device
Session type: Thematic Poster Session
Number: 3137
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. J. Sims, M. C. Patterson, S. K. Das, H. B. Buck, B. J. Lipworth (St Albans, United Kingdom). Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers. Eur Respir J 2002; 20: Suppl. 38, 3137

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
An improved bronchial provocation test with dry powder adenosine instead of nebulised adenosine monophosphate (AMP)
Source: International Congress 2017 – Monitoring asthma control
Year: 2017

Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 353s
Year: 2007

Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine
Source: Eur Respir J 2002; 19: 611-616
Year: 2002



PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020


Cellular and gas exchange responses to adenosine 5‘-monophosphate (AMP) challenge in mild asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 442s
Year: 2004

Effect of budesonide on AMP and methacholine airway responsiveness and sputum cellularity: a time-course study
Source: Eur Respir J 2001; 18: Suppl. 33, 163s
Year: 2001

Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 669s
Year: 2006

Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis
Source: Eur Respir J 2001; 17: 64-70
Year: 2001



Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Protective effect on AMP airway responsiveness after a single dose of fluticasone
Source: Eur Respir J 2004; 24 : 711-712
Year: 2004


The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 220s
Year: 2004

Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI
Source: Eur Respir J 2003; 21: 816-820
Year: 2003



Association between atopic status and airway reactivity to methacholine and adenosine monophosphate
Source: Eur Respir J 2001; 18: Suppl. 33, 102s
Year: 2001

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction
Source: Eur Respir J 2004; 23: 559-564
Year: 2004



Inhalation of dry powder INS1009 (DP-INS1009) does not activate the cough reflex in guinea pigs: a comparison with nebulized treprostinil.
Source: International Congress 2017 – Experimental PH
Year: 2017


Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 350s
Year: 2003

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003